로딩 중…
지수 로딩 중…
Hanmi Pharm. Co., Ltd.
128940· KOSPI· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩411,000-3.41%
2026-06-19
Price Chart
Hanmi Pharm. Co., Ltd.+38.62%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 5.27T KRW |
| Revenue | 1.55T KRW |
| Net Income | 178.03B KRW |
| Total Assets | 2.23T KRW |
| Net Assets | 1.48T KRW |
| Employees | 2,388 |
| Value | |
| P/E | 29.58x |
| P/B | 3.56x |
| PEG | 1.49x |
| P/S | 3.40x |
| EV/EBITDA | 71.04x |
| FCF Yield | 2.47% |
| Profitability | |
| ROE | 12.04% |
| ROA | 8.00% |
| Op. Margin | 16.29% |
| Revenue Growth | 0.51% |
| Earnings Growth | 19.90% |
| Financial Health | |
| Debt Ratio | 50.54% |
| Total Debt | 408.98B KRW |
| FCF | 130.05B KRW |
| Cash | 140.40B KRW |
| Current Ratio | 1.54x |
| Net Debt/EBITDA | 3.45x |
| Dividend | |
| Div. Yield | 0.47% |
| Div. Growth | 60.00% |
| Performance | |
| 1Y Return | 38.62% |
| 1M Return | -0.84% |
| From 52W High | -36.48% |
| 1Y MDD | -34.34% |
| Trading | |
| Volume | 112,568 shares |
| Foreign Own. | 13.60% |
| Per Share | |
| EPS | 13,460 KRW |
| BPS | 102,445 KRW |
Company Info
CEO 박재현
Employees 2,388
Founded 2010
HQ 경기도 화성시, KR
Hanmi Pharmaceutical was established in 2010 through a spin-off of its pharmaceutical manufacturing and sales division, comprising three domestic and international subsidiaries. It produces Rosuzet, Amozaltan, and Esomezol, while Hanmi Fine Chemical exports cephalosporin-based antibiotics globally, and Beijing Hanmi Pharmaceutical Co., Ltd. sells various products. The company focuses on innovative new drug development, having acquired numerous patents by 2025, and is optimizing manufacturing processes and saving energy to reduce greenhouse gas emissions by 30% by 2030. Hanmi Pharmaceutical is headquartered in Hwaseong-si, Gyeonggi-do.